Braun Stacey Associates Inc. Takes Position in Merck & Co., Inc. $MRK

Key Points

• Braun Stacey Associates opened a new position in Merck during the first quarter, buying 246,022 shares valued at about $29.6 million.
• Merck continues to draw strong institutional and analyst support; hedge funds own 76.07% of the stock, and the shares currently carry a Moderate Buy consensus with an average target price of $128.72.
• The company recently notched several pipeline and regulatory wins, including FDA approval for Keytruda-based treatment in triple-negative breast cancer and EU approval for Keytruda plus Padcev in bladder cancer, supporting future sales growth.

Braun Stacey Associates Inc. purchased a new position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 246,022 shares of the company's stock, valued at approximately $29,594,000.

Other institutional investors also recently added to or reduced their stakes in the company. Kingdom Financial Group LLC. acquired a new position in Merck & Co., Inc. during the fourth quarter worth $25,000. Abound Financial LLC acquired a new position in shares of Merck & Co., Inc. during the 4th quarter worth $26,000. Prosperity Bancshares Inc purchased a new position in shares of Merck & Co., Inc. in the 4th quarter valued at about $26,000. United Financial Planning Group LLC acquired a new stake in shares of Merck & Co., Inc. in the third quarter valued at about $31,000. Finally, High Note Wealth LLC boosted its holdings in Merck & Co., Inc. by 58.9% during the fourth quarter. High Note Wealth LLC now owns 294 shares of the company's stock worth $31,000 after buying an additional 109 shares in the last quarter. Hedge funds and other institutional investors own 76.07% of the company's stock.

Analyst Ratings Changes

A number of research analysts have issued reports on MRK shares. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $142.00 target price on shares of Merck & Co., Inc. in a report on Monday, March 30th. Wells Fargo & Company reduced their price objective on Merck & Co., Inc. from $150.00 to $145.00 and set an "overweight" rating for the company in a report on Friday, May 1st. Weiss Ratings lowered Merck & Co., Inc. from a "hold (c+)" rating to a "hold (c)" rating in a report on Friday, May 15th. Wall Street Zen upgraded Merck & Co., Inc. from a "hold" rating to a "buy" rating in a research report on Saturday, June 6th. Finally, CICC Research initiated coverage on shares of Merck & Co., Inc. in a research report on Wednesday. They issued an "outperform" rating and a $138.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and seven have given a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $128.72.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck announced FDA approval for Keytruda and Keytruda Qlex, each combined with Gilead’s Trodelvy, as a first-line treatment for PD-L1+ advanced triple-negative breast cancer, expanding a major revenue-driving franchise. Article Title
• Positive Sentiment: Merck also won EU approval for Keytruda plus Padcev in resectable muscle-invasive bladder cancer patients who cannot receive cisplatin chemotherapy, another label expansion that could support future sales. Article Title
• Positive Sentiment: Merck’s collaboration with Gilead continues to generate attention after positive HIV trial results, helping reinforce confidence in the company’s research pipeline and strategic partnerships. Article Title
• Neutral Sentiment: Merck was highlighted in CNBC’s “Final Trades,” which reflects ongoing market attention but does not by itself change the company’s fundamentals. Article Title
• Neutral Sentiment: Zacks noted that MRK is a trending stock, suggesting elevated investor interest rather than a specific new operating development. Article Title

Merck & Co., Inc. Stock Performance

Merck & Co., Inc. stock opened at $128.35 on Friday. Merck & Co., Inc. has a fifty-two week low of $76.66 and a fifty-two week high of $128.78. The company has a market capitalization of $316.99 billion, a price-to-earnings ratio of 36.15, a PEG ratio of 2.89 and a beta of 0.21. The stock has a fifty day moving average of $116.08 and a two-hundred day moving average of $114.33. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating analysts' consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The business had revenue of $16.29 billion for the quarter, compared to analyst estimates of $15.85 billion. During the same quarter last year, the company earned $2.22 earnings per share. The business's revenue for the quarter was up 4.9% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, analysts anticipate that Merck & Co., Inc. will post 5.17 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 8th. Investors of record on Monday, June 15th will be paid a dividend of $0.85 per share. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.6%. Merck & Co., Inc.'s dividend payout ratio is presently 95.77%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.